Navigation Links
Interferon does not slow or stop hepatitis C from worsening, study finds
Date:11/9/2007

Interferon does not slow or halt the progression of chronic hepatitis C and advanced liver disease in patients who havent responded to previous attempts to eradicate the disease, a national study in which the Saint Louis University School of Medicine participated has found.

Patients in the trial who were treated with interferon did experience a significant decrease in viral levels and liver inflammation, but the trial unequivocally demonstrated that treatment with long-term pegylated interferon also called peginterferon does not prevent the worsening of liver disease in patients whove failed prior treatments.

The results are this study are very clear long-term therapy with peginterferon for those with chronic hepatitis C is not effective in preventing progression of liver disease for patients who did not respond to an initial course of treatment, said Adrian Di Bisceglie, M.D., professor of internal medicine at Saint Louis University School of Medicine and chairman of the trials steering committee.

Furthermore, the relatively high rate of liver disease progression about 30 percent over nearly four years indicates the potential severity of chronic hepatitis C and emphasizes the importance of the ongoing search for new and more effective treatments, Di Bisceglie added.

Results of the study were reported by Di Bisceglie at the annual meeting of the American Association for the Study of Liver Disease in Boston this week.

Hepatitis C infects more than 100 million people worldwide and as many as 4 million people in the U.S. It ranks with alcohol abuse as the most common cause of chronic liver disease and leads to some 1,000 liver transplants in the U.S. each year.

The randomized, multi-site study involved 1,050 patients with chronic hepatitis C whod failed prior treatments to eradicate the infection. All had advanced liver fibrosis a gradual scarring of the liver that puts patients at risk for progressive liver disease.

The trial assessed whether long-treatment with peginterferon prevented the patients from developing cirrhosis, liver failure or liver cancer. Roughly half of the patients in the study received 90 micrograms of peginterferon in weekly injections for 3.5 years. The other half, the control group, underwent the same follow-up and care as the treated patients, including liver biopsies, quarterly clinic visits and blood tests.

At the end of the study, while patients treated with interferon did have significantly lower blood levels of the hepatitis C virus and less liver inflammation, 34.1 percent of them had experienced one or more of the following outcomes: excess fluid in the abdomen; brain and nervous system damage; cirrhosis (for those who did not have it initially); liver cancer; or death. Of patients in the control group, 33.8 percent experienced one or more of the outcomes.

Among treated patients, adverse side effects had caused 17 percent to stop peginterferon after 18 months and 30 percent to stop treatment by the end of the trial.


'/>"/>

Contact: Donn Walker
dwalke18@slu.edu
314-977-8015
Saint Louis University
Source:Eurekalert

Related medicine news :

1. Burgeoning Population of Hepatitis C Virus Patients in Need of Second- and Third-Line Treatment Options
2. Weight-based dosing of ribavirin improves outcomes for patients with hepatitis C
3. Stanford researchers find way to fight treacherous hepatitis B
4. Medical Services International Agrees to Retail the VScan Hepatitis B&C Test Kits in SE Asia
5. Hepatitis A Vaccine Best Bet to Treat Virus
6. Hepatitis C Testing Recommended for Anyone with a Tattoo
7. Is it pancreatitis in acute abdominal pain in acute viral hepatitis?
8. Dynavax and Merck & Co., Inc. Announce Partnership to Develop HEPLISAV(TM), an Investigational Hepatitis B Vaccine Currently in Phase 3
9. Pharmasset Presents R7128 14-Day Monotherapy Study Results for the Treatment of Chronic Hepatitis C
10. Phase II Study Shows that Nitazoxanide Significantly Improves Response to Standard of Care in Patients with Chronic Hepatitis C
11. HGS announces results of Phase 2B trial of Albuferon for chronic hepatitis C
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/27/2017)... ... July 27, 2017 , ... Conventus, New Jersey’s ... physicians, has launched a new educational series of webinars and podcasts to guide ... prescribing of pain medication. The first two episodes of the series, entitled “Pain ...
(Date:7/27/2017)... GA (PRWEB) , ... July 27, 2017 , ... ... to welcome Dr. Brent Sharpe who is now serving urology patients in ... Road, Suite 203 in Flowery Branch, and is open on Mondays, Tuesdays, Wednesdays, and ...
(Date:7/27/2017)... ... July 27, 2017 , ... Dr. ... Board of Oral Implantology/Implant Dentistry (ABOI/ID). After successfully completing an extensive two-day examination ... of dental implants . Dr. Kimowitz and his partner Dr. Hal Kimowitz, ...
(Date:7/27/2017)... ... July 27, 2017 , ... ... new patients with sleep apnea in Wayne, NJ to receive custom ... patients treat their sleep apnea with the use of custom-crafted oral appliances. Highly-trained ...
(Date:7/27/2017)... ... 2017 , ... Standard Process is ushering in a new era of innovation ... Research Campus (NCRC) in Kannapolis, North Carolina and by announcing a new leadership team, ... this year, occupying over 10,000 square feet on the first floor of the David ...
Breaking Medicine News(10 mins):
(Date:7/27/2017)... Ind., July 27, 2017  Zimmer Biomet Holdings, Inc. ... quarter ended June 30, 2017.  The Company reported second ... 1.1% over the prior year period, and an increase ... 240 basis points of contribution from the LDR Holding ... the second quarter of 2016, or 0.3% on a ...
(Date:7/27/2017)... Pharmaceutical Services, Inc. (NYSE: WST ) today ... updated financial guidance for the full-year 2017. ... Reported net sales of $397.6 million, a record ... at constant currency (organic) grew by 3.9%. ... $0.60 in the prior-year quarter. Second-quarter 2017 adjusted diluted ...
(Date:7/26/2017)... July 26, 2017 E.I. Medical Imaging (EIMI) ... Bimini SharkLab to custom design the worlds first ultrasound system to ... in their native habitat. In preparation for a piece produced ... Shark Week, Dr. Guttridge approached EIMI with the idea ... directly to hammerhead sharks underwater. ...
Breaking Medicine Technology: